Sirius Medical raises €4.4M to launch Sirius Pintuition

Sirius Medical raises €4.4M to launch Sirius Pintuition
An innovative breast cancer localization technology

Amsterdam, July 14th, 2020 – Investment company Holland Capital invests 4.4 million euros in Sirius Medical together with BOM Brabant Ventures and Curie Capital. The investment enables the company to accelerate the launch of Sirius Pintuition in both Europe and the US. Sirius Pintuition is an innovative technique that accurately localizes breast cancer tumors. A pipeline of complementary products and indications will be developed. Additional funding was provided by the Dutch Research Council (NWO), the Mibiton Fund, local development organizations, the Dutch government, unnamed business angels, management and existing shareholders of Sirius.

Sirius Medical, founded in February 2017, is a spin-off from the Netherlands Cancer Institute (NKI) and the University of Twente, with the aim of improving the health of breast cancer patients. It provides unique, affordable solutions that enable precise and efficient surgical removal of tumors. The Sirius Pintuition System was developed by and for surgeons addressing a clear clinical need with a solution that simply makes sense.

Hubert Martens, CEO of Sirius Medical, adds: “We are grateful for the trust provided by our investors in the Sirius Medical team. This investment allows us to accelerate the introduction of our innovative localization system to the market. In addition, the funding provided by our investors enables Sirius Medical to execute on its ambitious growth plans, broadening the clinical indications and technology offering for our customers”.

Localization of early breast cancer tumors
For patients diagnosed with breast cancer, breast conserving surgery is the cornerstone of a curative approach. As diagnostics have rapidly improved over the past decades, surgeons are facing increasingly challenging procedures as they have to locate ever smaller and earlier-stage tumours. Until now, patient-unfriendly metal anchor wires were used worldwide as surgical localization devices to guide the surgeon. Sirius Medical has now developed a method where a magnetic marker – a Pintuition “seed”, with the size of a grain of rice – is placed in the tumor days to weeks prior to surgery. During surgery, the Pintuition Detector provides real-time millimeter-accurate guidance to the Pintuition “seed”.

Jan-Frens van Giessel, healthcare partner at Holland Capital, says: “Sirius Medical has an innovative technology that not only enables a more accurate and more efficient localization of (early) breast cancer tumors, but also improves the quality of care for breast cancer patients. Therefore, the company fits very well within our investment strategy. We are proud to support this company in its growth ambitions.”
More information:

About Holland Capital
Over the past 37 years, Holland Capital has invested in more than 135 Dutch SMEs in a responsible and successful manner. With a clear investment strategy, Holland Capital is active in the growth markets of both healthcare and technology. The experienced and involved investment team knows what true entrepreneurship is like. With the joint goal of achieving growth, Holland Capital strives for an open, sustainable and professional relationship with the management teams of the companies in which it invests. Holland Capital is supported by a broad network of successful healthcare and technology entrepreneurs.

About BOM Brabant Ventures
BOM (the Brabant Development Agency) works together with businesses to create a strong, sustainable, and future-proof Brabant economy. BOM uses the Brabant Ventures label to focus, using knowledge and capital, on the accelerated and future-proof growth of ambitious Brabant start-ups and scaleups in the High-Tech Systems and Software, Agri-food, Life Sciences & Health, Maintenance, Supply Chain, and Bio-based Economy top industries.

About Curie Capital
Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and technology. The founding partners Mariette van der Velden and Han de Groot both have extensive experience in investing, entrepreneurship and managing companies across the full life cycle from start-up to (public) exit.

About Netherlands Cancer Institute
The Netherlands Cancer Institute was established on October 10, 1913. The institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theatres and 11 irradiation units for radiotherapy. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.